Validation of a novel CHX-A" derivative suitable for peptide conjugation:: Small animal PET/CT imaging using yttrium-86-CHX-A"-octreotide

被引:46
作者
Clifford, Thomas
Boswell, C. Andrew
Biddlecombe, Grainne B.
Lewis, Jason S.
Brechbiel, Martin W.
机构
[1] NCI, Radioimmune & Inorgan Chem Sect, Radiat Oncol Branch, Bethesda, MD 20892 USA
[2] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
关键词
D O I
10.1021/jm060317v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A versatile bifunctional chelating reagent based on a preorganized cyclohexyl derivative of DTPA (CHX-A ") has been developed for the convenient N-terminal labeling of peptides with metal ion radionuclides of Bi(III), In(III), Lu(III), or Y(III). This was achieved via the synthesis of a mono-N-hydroxysuccinimidyl penta-tert-butyl ester derivative of CHX-A" (trans-cyclohexyldiethylenetriaminepenta-acetic acid) featuring a glutaric acid spacer. Commercially obtained octreotide was modified at its N-terminus by this reagent in the solution phase, and its subsequent radiolabeling with In-111 (T-1/2 = 2.8 d) and Y-86 (T-1/2 = 14.7 h) demonstrated. Small animal PET/CT imaging results of Y-86-CHX-A"-octreotide in a somatostatin receptor-positive tumor-bearing rat model are presented for the validation of the novel agent.
引用
收藏
页码:4297 / 4304
页数:8
相关论文
共 55 条
[11]   Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics [J].
Chong, HS ;
Garmestani, K ;
Ma, DS ;
Milenic, DE ;
Overstreet, T ;
Brechbiel, MW .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (16) :3458-3464
[12]   Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis [J].
Dasgupta, P .
PHARMACOLOGY & THERAPEUTICS, 2004, 102 (01) :61-85
[13]   NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide [J].
Deshmukh, MV ;
Voll, G ;
Kühlewein, A ;
Mäcke, H ;
Schmitt, J ;
Kessler, H ;
Gemmecker, G .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) :1506-1514
[14]  
Fjalling M, 1996, J NUCL MED, V37, P1519
[15]   A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin™ [J].
Garmestani, K ;
Milenic, DE ;
Plascjak, PS ;
Brechbiel, MW .
NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (05) :599-606
[16]  
GODDU SM, 1994, J NUCL MED, V35, P521
[17]   Receptor targeting for tumor localisation and therapy with radiopeptides [J].
Heppeler, A ;
Froidevaux, S ;
Eberle, AN ;
Maecke, HR .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (09) :971-994
[18]  
HERZOG H, 1993, J NUCL MED, V34, P2222
[19]   86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487) -: a phase 1 clinical study:: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion [J].
Jamar, F ;
Barone, R ;
Mathieu, I ;
Walrand, S ;
Labar, D ;
Carlier, P ;
de Camps, J ;
Schran, H ;
Chen, T ;
Smith, MC ;
Bouterfa, H ;
Valkema, R ;
Krenning, EP ;
Kvols, LK ;
Pauwels, S .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (04) :510-518
[20]  
Kobayashi H, 1998, J NUCL MED, V39, P829